PerkinElmer Genetics launches new Lysosomal Storage Disorder panel

PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, announced today that its newborn screening laboratory service, PerkinElmer Genetics, has launched a new panel to screen for six Lysosomal Storage Disorders (LSDs) as an addition to its current newborn testing and diagnostics portfolio. The LSD Screening Panel tests for Krabbe disease, Gaucher's disease, Niemann-Pick disease (Type A and Type B), Pompe disease, Fabry disease and MPS I.

"The new LSD panel is the latest addition to our diagnostic and screening services portfolio of more than 50 metabolic disorders. It enhances the ability to detect six additional genetic disorders within 72 hours of specimen receipt, enabling earlier clinical intervention for better neonatal health," said Jim Corbett, president, Diagnostics, PerkinElmer. "While the primary goal is to provide information that improves a newborn's quality of life and a definitive diagnosis for parents, such tests also have the potential to lower palliative healthcare costs for families and insurers, due to early diagnosis."

Each LSD results from different genetic mutations that translate into a deficiency in enzyme activity. However, they all share a common biochemical characteristic - all lysosomal disorders originate from an abnormal accumulation of substances inside the lysosome. The lysosome is responsible for converting cell waste into reusable matter for cell function. Enzymes catalyze the breakdown of this unwanted material, but in individuals with an LSD, the necessary enzyme is missing or exists in an insufficient amount. This causes the cell waste to accumulate in excess within the cell. Symptoms of LSDs can include muscle damage, respiratory difficulties, bone abnormalities, joint stiffness, burning sensations, enlarged liver or spleen, seizures and loss of learned skills. When left untreated, severe deficiencies may result in death.

The collective group of approximately 50 known LSDs has an incidence rate between 1 out of 5,000 and 1 out of 10,000. Although there is no known cure for LSDs, early detection allows doctors to plan for treatment which involves addressing symptoms that may occur between infancy and adulthood. Emerging therapies for LSDs include enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) using bone marrow or umbilical cord blood as a source of healthy stem cells.

Source:

PerkinElmer, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PerkinElmer. (2019, June 18). PerkinElmer Genetics launches new Lysosomal Storage Disorder panel. News-Medical. Retrieved on December 10, 2019 from https://www.news-medical.net/news/20111028/PerkinElmer-Genetics-launches-new-Lysosomal-Storage-Disorder-panel.aspx.

  • MLA

    PerkinElmer. "PerkinElmer Genetics launches new Lysosomal Storage Disorder panel". News-Medical. 10 December 2019. <https://www.news-medical.net/news/20111028/PerkinElmer-Genetics-launches-new-Lysosomal-Storage-Disorder-panel.aspx>.

  • Chicago

    PerkinElmer. "PerkinElmer Genetics launches new Lysosomal Storage Disorder panel". News-Medical. https://www.news-medical.net/news/20111028/PerkinElmer-Genetics-launches-new-Lysosomal-Storage-Disorder-panel.aspx. (accessed December 10, 2019).

  • Harvard

    PerkinElmer. 2019. PerkinElmer Genetics launches new Lysosomal Storage Disorder panel. News-Medical, viewed 10 December 2019, https://www.news-medical.net/news/20111028/PerkinElmer-Genetics-launches-new-Lysosomal-Storage-Disorder-panel.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
New PerkinElmer assay kits use AlphaLISA technology for biotherapeutic drug development